Cannabix
Technologies to Present Marijuana Breathalyzer Technology at
International Association for Chemical Testing (IACT) Conference in
California
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia,
Canada -- April 22, 2024 -- InvestorsHub NewsWire -- Cannabix
Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix")
developer of marijuana breathalyzer devices for law enforcement and
the workplace reports that it will be presenting at the
International Association for Chemical Testing (IACT) conference in
April.
Cannabix's Dr. Bruce Goldberger
Ph.D., will be presenting on Science &
Technology Behind Cannabis Breath Testing
and the Company's marijuana
breathalyzer system at the conference workshop session. IACT is
composed of governmental agency personnel involved in chemical
testing related to traffic safety. IACT members are scientific and
criminal justice professionals, including forensic scientists,
regulatory inspectors, and law enforcement personnel with
representatives from a majority of states and international
members. IACT has standing committees to address various areas
including legislation, training, new equipment and procedures and
manufacturers of breath testing equipment.
The Cannabis Breath
Testing workshop at IACT 2024 is
designed to provide background information regarding the
pharmacokinetics and pharmacodynamics of cannabinoids in breath,
present the current technology for collection devices from
commercial vendors, and discuss the necessary laboratory workflows
and analytical considerations when testing these
samples.
Dr. Bruce Goldberger is a professor
and the former Chief of the Forensic Medicine Division in the
Department of Pathology, Immunology and Laboratory Medicine in the
College of Medicine at the University of Florida. Dr. Goldberger
served as Director of the University of Florida forensic toxicology
laboratory for 30 years. Dr. Goldberger is the Principal
Investigator of the Florida Drug-Related Outcomes Surveillance and
Tracking System and Co-investigator of the National Drug Early
Warning System. Dr. Goldberger is a consultant for the Centers for
Disease Control and Prevention's National Center for Injury
Prevention and Control, Overdose Mortality Team, and the National
Center for Health Statistics, Division of Vital Statistics. Dr.
Goldberger is a consultant and senior advisor to Cannabix
Technologies Inc.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana and alcohol breathalyzer technologies for
law enforcement, workplaces and laboratories. Cannabix is
developing delta-9 THC and alcohol screening devices. Delta-9 THC
is the psychoactive component of marijuana that causes impairment.
Breath testing for delta-9 THC would allow employers and law
enforcement to identify recent marijuana use.
Cannabix is the developer of Breath Logix Series of autonomous
breath alcohol detection devices for employers and a range of other
settings.
We seek Safe
Harbor.
On behalf of
the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the
Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains
forward-looking information that involves various risks and
uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently selling
commercial breathalyzers. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com